General Information About Triomune
Comprised of 150mg of lamivudine, 200mg of nevirapine, and 30mg of stavudine, this pharmaceutical inhibits the replication of human immunodeficiency virus (HIV).
Triomune is suitable for patients with HIV infections. You should take 1 tablet of Triomune-30 twice daily, 12 hours apart, if your body weight is less than 60kg. If your body weight is greater than 60kg, you may need to take Triomune-40. You may only be prescribed this medication if you have completed a 2-week lead-in treatment period comprised of 300mg of lamivudine daily, 30mg of stavudine twice daily, and 200mg of nevirapine once daily. If you miss a dose, take it as soon as possible. Do not double your dose.
If you are allergic to lamivudine, stavudine, nevirapine or any other ingredients in Triomune, you should not seek this treatment. Additionally, if you have a severe hepatic disorder or are in end-stage renal failure, you should not use Triomune-30.
It should be noted that certain side effects have been reported with Triomune use. Reported reactions include:
- Upper abdominal pain;
- And fatigue.
Rarer side effects have also been reported for this pharmaceutical, including:
- And allergic reactions.
Following therapy using Triomune, you may experience certain health complications.
- Lactic acidosis: Marked by an accumulation of lactic acid in the bloodstream, this condition is commonly observed in women, obese individuals, and those with prolonged nucleoside exposure. Fatal lactic acidosis has been reported in pregnant patients prescribed with a combination of stavudine, didanosine, and other antiretroviral agents.
- Immune reconstitution syndrome: This condition has been seen in some patients whose immune system begins to recover and respond to previous opportunistic infections after taking Triomune. This may result in overwhelming inflammatory responses.
- Fat redistribution: Patients on multiple antiretroviral therapies may experience the accumulation and/or redistribution of fat. This can include central obesity, the formation of buffalo humps, breast enlargement, facial wasting, and peripheral wasting.
Since there are 3 active ingredients in Triomune, there is a greater risk for interactions.
- Drugs that may interact with lamivudine:
- Antiretroviral agents that treat HIV Infections (e.g. zalcitabine);
- Antiviral agents that treat hepatitis (e.g. ribavirin).
- Drugs that may interact with nevirapine:
- Antiretroviral agents (e.g. atazanavir, lopinavir, fosamprenavir);
- Analgesics (e.g. methadone);
- Antibiotics (e.g. clarithromycin, rifabutin, rifampin);
- Antifungals (e.g. itraconazole, fluconazole, ketoconazole).
- Drugs that may interact with stavudine:
- Antiretroviral agents (e.g. zidovudine);
- Cancer chemotherapy agents (e.g. doxorubicin).
If you are taking any of these medications, please consult your doctor before receiving treatment with Triomune.
Pregnancy & Lactation
Stavudine and lamivudine are classified under category C in the FDA’s Pregnancy Categories, whilst nevirapine is classified under category B. Therefore, pregnant women should only take this drug if its potential benefits justify any potential risks to the fetus. This drug should be used with caution when treating breastfeeding mothers.
Any suspected overdose should be immediately reported to and monitored by a healthcare professional.
Alternative Brand Names
Stavex LN and Virolans contain the same ingredients and provide the same therapeutic benefits as Triomune.
Reviews are only written by verified customers who have purchased this product.